BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, December 24, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 9, 2008

View Archived Issues

Novel class of bacterial topoisomerase II inhibitors reported by Pharmacia

Read More

Indomethacin silicon-amide derivatives may have improved physiological activity

Read More

First-in-class inhibitors of EWS-FLI1 protein potentially effective against Ewing's sarcoma

Read More

Johnson & Johnson's R-231857 shows benefit in a model of cognitive impairment in healthy men

Read More

Lilly to fund rodent studies of Corcept's selective GRII receptor antagonist CORT-108297

Read More

UNC to conduct phase IIa clinical trial of Discovery's KL-4 surfactant in CF

Read More

Recent GlaxoSmithKline patent claims new compounds for cardiovascular conditions

Read More

Mutual submits NDA to FDA for antihyperlipidemic drug MPC-028

Read More

U.S. Army to provide Neuren with additional funding for phase II trial of NNZ-2566

Read More

Protox completes enrollment in phase II trial of PRX-302 in BPH

Read More

Novel antipsychotic profile described for Pierre Fabre's F-16615

Read More

Novel PAR1 antagonists discovered at Pierre Fabre

Read More

Ardea Biosciences describes discovery of MEK inhibitor RDEA-119

Read More

Structure-activity relationship analysis of novel IKKbeta inhibitors leads to AS-1950930

Read More

Polidocanol sclerotherapy product is effective in varicose vein treatment

Read More

Sumatriptan oral spray effective in migraine headache relief at lower dose than tablets

Read More

Palifosfamide studied in new phase II trial for soft tissue sarcoma

Read More

iCo-009 advances towards clinic

Read More

MDRNA awarded further funding for research in RNA inhibition of influenza

Read More

GMI-1070 enters clinic for vaso-occlusive crisis of sickle cell disease

Read More

SARcode begins phase I trial for LFA-1 product candidate

Read More

Histalean begins phase II female obesity study

Read More

Progenics starts phase I prostate cancer study of PSMA antibody-drug conjugate

Read More

New treatment options for urinary incontinence described in recent Toray patent

Read More

BioSante clinical results for Pill-Plus triple hormone therapy

Read More

Pharmasset reports preliminary results of R-7128 proof-of-concept study in HCV

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 23, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 23, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Illustration of brain with electrical activity background

    ABS-1230 controls seizures in KCNT1-driven severe epilepsy

    BioWorld Science
    Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
  • Acute myeloid leukemia illustration

    Apollo’s APL-4098 shows potent antileukemic effects

    BioWorld Science
    Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing